- Open Access
C-peptide persistence in type 1 diabetes: ‘not drowning, but waving’?
BMC Medicine volume 17, Article number: 179 (2019)
One hundred years ago, diabetes was considered to be one disease, although with marked clinical heterogeneity. Adults who developed diabetes could often manage for years with diet alone, but children usually died within 6 months of diagnosis . Once discovered, insulin was used successfully to treat these children. Thereafter, these children were classified as having insulin-dependent diabetes, which was later re-termed as type 1 diabetes with a dependence on insulin to survive. Patients with all types of diabetes were classified as having non-insulin-dependent or type 2 diabetes, although many eventually required insulin treatment themselves, despite their less aggressive disease course. The development of radioimmunoassays for insulin, proinsulin and its cleaved section C-peptide, only tended to confirm that children with diabetes had little or no insulin, while adults often had substantial amounts. This binary approach to diabetes stratification i.e., that patients do or do not secrete insulin has recently been challenged, notably by exploiting immunogenetics and more sensitive protein assays to define the diabetes spectrum and its heterogeneity [1,2,3].
In their BMC Medicine article, McKeigue and colleagues  explored detectable C-peptide in a large cohort from Scotland, representing a cross-sectional analysis of one-third of the population diagnosed with type 1 diabetes over age 16 years. Patients were diagnosed both clinically, by exclusion of other causes, and with one or more diabetes-associated autoantibody. Detectable C-peptide levels varied substantially, with age and disease duration being key variables: C-peptide was lowest in the youngest 15 years from diagnosis (19%) and highest in the oldest, close to diagnosis (92%). Genetic analysis using single nucleotide polymorphisms indicated some heritability for C-peptide variance (26%) . As expected, both human leucocyte antigen (HLA) and insulin gene regions reflected the most aggressive disease process. Persistence of C-peptide was associated with gene risk scores for both type 1 and type 2 diabetes, but also strikingly with HLA regions, not accounted for by high gene-risk HLA serotypes. In other words, the genetics of C-peptide persistence may be distinct from the genetics of C-peptide loss, invoking multiple genetic networks linked to both type 1 and type 2 diabetes.
This paper opens a can of worms regarding our understanding of diabetes and its stratification. The apparent categorical difference between the two major types of diabetes has been challenged, with the realisation that some adult-onset type 1 diabetes cases may not initially need insulin treatment and can have similar C-peptide levels as in type 2 cases [1, 3]. The characteristic type 1 diabetes inflammatory infiltrate, or insulitis, turns out to be not so prevalent as thought, and has been dubbed ‘the elusive lesion’ . Indeed, islet beta-cell function and mass may be compromised in multiple ways, e.g. apoptosis and de-differentiation. There may also be many mechanisms to explain the persistence of C-peptide secretion, including new growth, trans-differentiation with the appearance of islet delta cells or, perhaps, distinct beta-cells, impervious to aggressive autoimmune attack . However, any explanation must account for the remarkable spectrum of C-peptide, in which decline follows a pattern of ‘younger, faster, greater’, while C-peptide persistence is also associated with genes distinct from type 1 diabetes susceptibility genes, implicating type 2 diabetes networks .
At first glance, there appears to be a hierarchy of beta-cell dysfunction. We now know that proinsulin is retained, even as C-peptide response declines. However, when C-peptide is low or absent, both C-peptide and proinsulin fail to respond to stimuli . Given histological evidence that beta-cells persist long after diagnosis, the question arises: are these beta-cells ‘sleeping’ and could they be aroused? In other words, are they ‘stunned’, or functionally dead [5, 7]? The fact that proinsulin levels are detectable, even when C-peptide is not, supports the former argument . Since proinsulin, C-peptide and insulin are secreted in equimolar quantities, but insulin is largely extracted by the liver, increased proinsulin:C-peptide (PL:CP) ratios imply accumulation and secretion of inadequately processed proinsulin, a hallmark of endoplasmic reticulum (ER) dysfunction. A cell that is unable to respond to its primary stimulus is called a ‘stunned’ cell and has the intrinsic capacity to restore competence . In the context of diabetes, one feature of such ‘stunned’ cells, is that there is not only a mismatch between insulin secretion and glucose stimulus, but also that the change can recover. ‘Stunned’ beta-cells are probably a feature of both type 2 and type 1 diabetes and can anticipate and predict both types . Such ‘stunned’ cells are conceptually distinct from ER stress, although both imply a dysfunctional beta-cell. Indeed, evidence of ER stress, using this PL:CP ratio, can be found in children at risk of type 1 diabetes and, in them, predicts the disease, especially in children under the age of 10 years [6, 7].
Many years ago, we and others found the same altered PL:CP ratio: before type 1 diabetes, but also in identical co-twins of children with type 1 diabetes and in non-HLA identical siblings, who were themselves estimated to be at low disease risk [8, 9]. Such an altered PL:CP ratio also predicated type 1 diabetes . Despite using different immunoassays, these changes in PL:CP ratio give the results coherence, although none can be certain it was entirely intact proinsulin that was being measured [6, 8,9,10]. The idea that changes in PL:CP ratio could be familial raises the possibility that shared genetic and/or environmental effects play a role in beta-cell susceptibility to damage. That much would be consistent with the evidence in the present paper that persistence of C-peptide, as against decline, is both genetically determined and associated with type 2 diabetes gene risk .
The present data open new avenues for research and hints at various pathways that might have a differential impact on disease risk, rate of disease progression and failure of the disease process to eliminate all beta-cells in the pancreatic islets. Whether sleeping or dead, the possibility that some cells are ‘not drowning, but waving’, suggests restoration of beta-cell function may yet be feasible.
Availability of data and materials
Ahlqvist E, Storm P, Käräjämäki A, Martinell M, Dorkhan M, Carlsson A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6:361–9.
Cousminer DL, Ahlqvist E, Mishra R, Andersen MK, Chesi A, Hawa MI, et al. First genome-wide association study of latent autoimmune diabetes in adults reveals novel insights linking immune and metabolic diabetes. Diabetes Care. 2018;41:2396–403.
Hawa MI, Kolb H, Schloot N, Beyan H, Paschou SA, Buzzetti R, et al. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: action LADA 7. Diabetes Care. 2013;36:908–13.
McKeigue P, et al. Persistent C-peptide secretion in type 1 diabetes and its relationship to the genetic architecture of diabetes. BMC Med. 2019;17:165.
Oram RA, Sims EK, Evans-Molina C. Beta cells in type 1 diabetes: mass and function; sleeping or dead? Diabetologia. 2019;62:567–77.
Sims EK, Bahnson HT, Nyalwidhe J, Haataja L, Davis AK, Speake C, et al. Proinsulin secretion is a persistent feature of type 1 diabetes. Diabetes Care. 2019;42:258–64.
Ferrannini E, Mari A, Nofrate V, Sosenko JM, Skyler JS, DPT-1 Study Group. Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset. Diabetes. 2010;59:679–85.
Heaton DA, Millward BA, Gray P, Tun Y, Hales CN, Pyke DA, et al. Evidence of beta cell dysfunction which does not lead on to diabetes: a study of identical twins of insulin dependent diabetics. BMJ. 1987;294:145–6.
Hartling SG, Lindgren F, Dahlqvist G, Persson B, Binder C. Elevated proinsulin in healthy siblings of IDDM patients independent of HLA identity. Diabetes. 1989;38:1271–4.
Truyen I, De Pauw P, Jørgensen PN, Van Schravendijk C, Ubani O, Decochez K, et al. Proinsulin levels and the proinsulin:c-peptide ratio complement autoantibody measurement for predicting type 1 diabetes. Diabetologia. 2005;48:2322–9.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Leslie, R.D., Vartak, T. C-peptide persistence in type 1 diabetes: ‘not drowning, but waving’?. BMC Med 17, 179 (2019). https://doi.org/10.1186/s12916-019-1415-5
- Type 1 diabetes
- Gene risk scores
- Insulin secretion